Clinical Challenges in the Biopsychosocial Interface

Update on Psychosomatics for the 21st Century

Editor(s): Balon, R. (Detroit, MI)
Wise, T.N. (Falls Church, VA)
 

Fibromyalgia and Chronic Fatigue: The Underlying Biology and Related Theoretical Issues

Romano G.F.a · Tomassi S.b · Russell A.a · Mondelli V.a · Pariante C.M.a

Author affiliations

aStress, Psychiatry and Immunology Laboratory, Department of Psychological Medicine, Institute of Psychiatry, King's College London, London, UK; bSection of Psychiatry, Department of Public Health and Community Medicine, University of Verona, Verona, Italy

Related Articles for ""

Balon R, Wise TN (eds): Clinical Challenges in the Biopsychosocial Interface. Update on Psychosomatics for the 21st Century. Adv Psychosom Med. Basel, Karger, 2015, vol 34, pp 61-77

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of  

Published online: March 30, 2015
Cover Date: 2015

Number of Print Pages: 17
Number of Figures: 2
Number of Tables: 3

ISBN: 978-3-318-02966-6 (Print)
eISBN: 978-3-318-02967-3 (Online)

Abstract

There is an increasing interest in understanding the biological mechanism underpinning fibromyalgia (FM) and chronic fatigue syndrome (CFS). Despite the presence of mixed findings in this area, a few biological systems have been consistently involved, and the increasing number of studies in the field is encouraging. This chapter will focus on inflammatory and oxidative stress pathways and on the neuroendocrine system, which have been more commonly examined. Chronic inflammation, together with raised levels of oxidative stress and mitochondrial dysfunction, has been increasingly associated with the manifestation of symptoms such as pain, fatigue, impaired memory, and depression, which largely characterise at least some patients suffering from CFS and FM. Furthermore, the presence of blunted hypothalamic-pituitary-adrenal axis activity, with reduced cortisol secretion both at baseline and in response to stimulation tests, suggests a role for the hypothalamic-pituitary-adrenal axis and cortisol in the pathogenesis of these syndromes. However, to what extent these systems' abnormalities could be considered as primary or secondary factors causing FM and CFS has yet to be clarified.

© 2015 S. Karger AG, Basel




References

  1. Centers for Disease Control and Prevention: Chronic Fatigue Syndrome (CFS) Case Definition. Atlanta, GA, Centers for Disease Control and Prevention, 2012.
  2. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A: The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994;121:953-959.
  3. Reeves WC, Lloyd A, Vernon SD, et al: Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv Res 1994;3:1-9.
  4. Centers for Disease Control and Prevention: Fibromyalgia. Atlanta, GA, Centers for Disease Control and Prevention, 2012.
  5. Wolfe F, Clauw DJ, Fitzcharles MA, et al: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62:600-610.
  6. Wessely S, Nimnuan C, Sharpe M: Functional somatic syndromes: one or many? Lancet 1999 Sep;354:936-939.
  7. Maes M, Twisk FNM: Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. BMC Med 2010;8:35.
  8. Harvey S, Wessely S: Chronic fatigue syndrome: identifying zebras amongst the horses. BMC Med 2009;7:58.
  9. Abbas AK, Lichtman AHH, Pillai S: Cellular and Molecular Immunology: with STUDENT CONSULT Online Access, ed 7. Philadelphia, Elsevier Health Sciences, 2011.
  10. Burdette SD, Parilo MA, Kaplan LJ, Bailey H: Systemic inflammatory response syndrome. 2014. http://emedicine.medscape.com/article/168943-overview (accessed June 19, 2014).
  11. Dantzer R, Kelley KW: Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007;21:153-160.
  12. Carmichael MD, Davis JM, Murphy EA, et al: Role of brain IL-1beta on fatigue after exercise-induced muscle damage. Am J Physiol Regul Integr Comp Physiol 2006;291:R1344-R1348.
  13. Kelley KW, Bluthe RM, Dantzer R, et al: Cytokine-induced sickness behavior. Brain Behav Immun 2003;17:S112-S118.
  14. Capuron L, Miller AH: Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011;130:226-238.
  15. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M: Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002;72:237-241.
  16. Bull SJ, Huezo-Diaz P, Binder EB, et al: Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2009;14:1095-1104.
  17. Su K-P, Huang S-Y, Peng C-Y, et al: Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry 2010;67:550-557.
  18. Strand V, Singh JA: Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2007;13:S237-S251.
  19. Tyring S, Gottlieb A, Papp K, et al: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35.
  20. Baumeister D, Russell A, Pariante C, Mondelli V: Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors. Soc Psychiatry Psychiatr Epidemiol 2014;49:841-849.
  21. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS: Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2014;53C:23-34.
  22. Lasselin J, Capuron L: Chronic low-grade inflammation in metabolic disorders: relevance for behavioral symptoms. Neuroimmunomodulation 2014;21:95-101.
  23. Silverman MN, Heim CM, Nater UM, Marques AH, Sternberg EM: Neuroendocrine and immune contributors to fatigue. PM R 2010;2:338-346.
  24. Anderson G, Berk M, Maes M: Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome. Acta Psychiatr Scand 2014;129:83-97.
  25. Brenu EW, Huth TK, Hardcastle SL, et al: Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int Immunol 2014;26:233-242.
  26. Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG: Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009;7:96.
  27. Skowera A, Cleare A, Blair D, Bevis L, Wessely SC, Peakman M: High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol 2004;135:294-302.
  28. Zhang H-Y, Liu Z-D, Hu C-J, Wang D-X, Zhang Y-B, Li Y-Z: Up-regulation of TGF-β1 mRNA expression in peripheral blood mononuclear cells of patients with chronic fatigue syndrome. J Formos Med Assoc 2011;110:701-704.
  29. Tomoda A, Joudoi T, Rabab E-M, Matsumoto T, Park TH, Miike T: Cytokine production and modulation: comparison of patients with chronic fatigue syndrome and normal controls. Psychiatry Res 2005;134:101-104.
  30. Maes M, Twisk FNM, Kubera M, Ringel K: Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-alpha, PMN-elastase, lysozyme and neopterin. J Affect Disord 2012;136:933-939.
  31. Bote ME, Garca JJ, Hinchado MD, Ortega E: Inflammatory/stress feedback dysregulation in women with fibromyalgia. Neuroimmunomodulation 2012;19:343-351.
  32. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH: Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 2001;40:743-749.
  33. Togo F, Natelson BH, Adler GK, et al: Plasma cytokine fluctuations over time in healthy controls and patients with fibromyalgia. Exp Biol Med (Maywood) 2009;234:232-240.
  34. Nakamura T, Schwander SK, Donnelly R, et al: Cytokines across the night in chronic fatigue syndrome with and without fibromyalgia. Clin Vaccine Immunol 2010;17:582-587.
  35. Gür A, Karakoç M, Nas K, et al: Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002;29:358-361.
  36. Wang H, Buchner M, Moser MT, Daniel V, Schiltenwolf M: The role of IL-8 in patients with fibromyalgia: a prospective longitudinal study of 6 months. Clin J Pain 2009;25:1-4.
  37. Buchwald D, Wener MH, Pearlman T, Kith P: Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol 1997;24:372-376.
  38. Raison CL, Lin JMS, Reeves WC: Association of peripheral inflammatory markers with chronic fatigue in a population-based sample. Brain Behav Immun 2009;23:327-337.
  39. Spence VA, Kennedy G, Belch JJF, Hill A, Khan F: Low-grade inflammation and arterial wave reflection in patients with chronic fatigue syndrome. Clin Sci (Lond) 2008;114:561-566.
  40. Xiao Y, Haynes WL, Michalek JE, Russell IJ: Elevated serum high-sensitivity C-reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate. Rheumatol Int 2013;33:1259-1264.
  41. Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G: Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009;8:287-291.
  42. Morris G, Maes M: A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome. Metab Brain Dis 2013;28:523-540.
  43. Robertson MJ, Schacterle RS, Mackin GA, et al: Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression. Clin Exp Immunol 2005;141:326-332.
  44. Curriu M, Carrillo J, Massanella M, et al: Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. J Transl Med 2013;11:68.
  45. Mihaylova I, DeRuyter M, Rummens J, Bosmans E, Maes M: Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells. Neuro Endocrinol Lett 2007;28:477-483.
  46. Aoki T, Miyakoshi H, Usuda Y, Herberman R: Low NK syndrome and its relationship to chronic fatigue syndrome. Clin Immunol Immunopathol 1993;69:253-265.
  47. Poggi A, Zocchi MR: NK Cell autoreactivity and autoimmune diseases. Front Immunol 2014;5:27.
  48. Bradley AS, Ford B, Bansal AS: Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls. Clin Exp Immunol 2013;172:73-80.
  49. Tanaka S, Kuratsune H, Hidaka Y, et al: Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int J Mol Med 2003;12:225-230.
  50. Bassi N, Amital D, Amital H, Doria A, Shoenfeld Y: Chronic fatigue syndrome: characteristics and possible causes for its pathogenesis. Isr Med Assoc J 2008;10:79-82.
  51. Werle E, Fischer HP, Müller A, Fiehn W, Eich W: Antibodies against serotonin have no diagnostic relevance in patients with fibromyalgia syndrome. J Rheumatol 2001;28:595-600.
  52. Maes M, Mihaylova I, Leunis JC: In chronic fatigue syndrome, the decreased levels of omega-3 poly-unsaturated fatty acids are related to lowered serum zinc and defects in T cell activation. Neuro Endocrinol Lett 2005;26:745-751.
  53. Miyamae T, Seki M, Naga T, et al: Increased oxidative stress and coenzyme Q10 deficiency in juvenile fibromyalgia: amelioration of hypercholesterolemia and fatigue by ubiquinol-10 supplementation. Redox Rep 2013;18:12-19.
  54. Steinau M, Unger ER, Vernon SD, Jones JF, Rajeevan MS: Differential-display PCR of peripheral blood for biomarker discovery in chronic fatigue syndrome. J Mol Med (Berl) 2004;82:750-755.
  55. Fang H, Xie Q, Boneva R, Fostel J, Perkins R, Tong W: Gene expression profile exploration of a large dataset on chronic fatigue syndrome. Pharmacogenomics 2006;7:429-440.
  56. Kerr JR, Petty R, Burke B, et al: Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Infect Dis 2008;197:1171-1184.
  57. Carlo-Stella N, Badulli C, De Silvestri A, et al: A first study of cytokine genomic polymorphisms in CFS: positive association of TNF-857 and IFNgamma 874 rare alleles. Clin Exp Rheumatol 2006;24:179-182.
  58. Blankfield A: Kynurenine pathway pathologies: do nicotinamide and other pathway co-factors have a therapeutic role in reduction of symptom severity, including chronic fatigue syndrome (CFS) and fibromyalgia (FM). Int J Tryptophan Res 2013;6:39-45.
  59. Badawy AA-B, Morgan CJ, Llewelyn MB, Albuquerque SRJ, Farmer A: Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome. J Psychopharmacol 2005;19:385-391.
  60. Vassallo CM, Feldman E, Peto T, Castell L, Sharpley AL, Cowen PJ: Decreased tryptophan availability but normal post-synaptic 5-HT2c receptor sensitivity in chronic fatigue syndrome. Psychol Med 2001;31:585-591.
  61. Maes M, Galecki P, Verkerk R, Rief W: Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett 2011;32:264-273.
  62. Nijs J, Meeus M, Van Oosterwijck J, et al: Treatment of central sensitization in patients with ‘unexplained' chronic pain: what options do we have? Expert Opin Pharmacother 2011;12:1087-1098.
  63. Nelson DDL, Lehninger AL, Cox MM: Lehninger Principles of Biochemistry, ed 6. New York, W.H. Freeman, 2013.
  64. Alberts B, Bray D, Hopkin K, et al: Essential Cell Biology, ed 4. New York, Garland Science, 2013.
  65. Murphy MP: How mitochondria produce reactive oxygen species. Biochem J 2009;417:1-13.
  66. Maes M: Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry 2009;22:75-83.
  67. Morris G, Maes M: Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis 2014;29:19-36.
  68. Maes M, Mihaylova I, Kubera M, Bosmans E: Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro Endocrinol Lett 2007;28:463-469.
  69. Bazan NG: Metabolism of arachidonic acid in the retina and retinal pigment epithelium: biological effects of oxygenated metabolites of arachidonic acid. Prog Clin Biol Res 1989;312:15-37.
  70. Closa D, Folch-Puy E: Oxygen free radicals and the systemic inflammatory response. IUBMB Life 2004;56:185-191.
  71. McIver KL, Evans C, Kraus RM, Ispas L, Sciotti VM, Hickner RC: NO-mediated alterations in skeletal muscle nutritive blood flow and lactate metabolism in fibromyalgia. Pain 2006;120:161-169.
  72. Chung HY, Lee EK, Choi YJ, et al: Molecular inflammation as an underlying mechanism of the aging process and age-related diseases. J Dent Res 2011;90:830-840.
  73. Melnikova T, Savonenko A, Wang Q, et al: Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 2006;141:1149-1162.
  74. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E: Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett 2009;30:462-469.
  75. Cordero MD, Cano-Garcìa FJ, Alcocer-Gòmez E, de Miguel M, Sànchez-Alcàzar JA: Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q 10 effect on clinical improvement. PLoS One 2012;7:e35677.
  76. Cordero MD, Cotàn D, Del-Pozo-Martìn Y, et al: Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathologic alterations in blood mononuclear cells in a fibromyalgia patient. Nutrition 2012;28:1200-1203.
  77. Morris G, Anderson G, Dean O, et al: The glutathione system: a new drug target in neuroimmune disorders. Mol Neurobiol 2014;50:1059-1084.
  78. Morris G, Maes M: Increased nuclear factor κβ and loss of p53 are key mechanisms in Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med Hypotheses 2012;79:607-613.
  79. Cordero MD, de Miguel M, Carmona-López I, Bonal P, Campa F, Moreno-Fernández AM: Oxidative stress and mitochondrial dysfunction in fibromyalgia. Neuro Endocrinol Lett 2010;31:169-173.
  80. Cordero MD, Moreno-Fernàndez AM, Carmona-Lòpez MI, et al: Mitochondrial dysfunction in skin biopsies and blood mononuclear cells from two cases of fibromyalgia patients. Clin Biochem 2010;43:1174-1176.
  81. Castro-Marrero J, Cordero MD, Sáez-Francas N, et al: Could mitochondrial dysfunction be a differentiating marker between chronic fatigue syndrome and fibromyalgia? Antioxid Redox Signal 2013;19:1855-1860.
  82. Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJF: Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med 2005;39:584-589.
  83. Chung CP, Titova D, Oeser A, et al: Oxidative stress in fibromyalgia and its relationship to symptoms. Clin Rheumatol 2009;28:435-438.
  84. Maes M, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E: Increased plasma peroxides as a marker of oxidative stress in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med Sci Monit 2011;17:SC11-SC15.
  85. Jammes Y, Steinberg JG, Mambrini O, Brégeon F, Delliaux S: Chronic fatigue syndrome: Assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med 2005;257:299-310.
  86. Richards RS, Wang L, Jelinek H: Erythrocyte oxidative damage in chronic fatigue syndrome. Arch Med Res 2007;38:94-98.
  87. Klein R, Berg PA: High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. Eur J Med Res 1995;1:21-26.
  88. Maes M, Mihaylova I, Leunis J-C: Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett 2006;27:615-621.
  89. Meeus M, Nijs J, Hermans L, Goubert D, Calders P: The role of mitochondrial dysfunctions due to oxidative and nitrosative stress in the chronic pain or chronic fatigue syndromes and fibromyalgia patients: peripheral and central mechanisms as therapeutic targets? Expert Opin Ther Targets 2013;17:1081-1089.
  90. Myhill S, Booth NE, McLaren-Howard J: Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009;2:1-16.
  91. VanNess JM, Stevens SR, Bateman L, Stiles TL, Snell CR: Postexertional malaise in women with chronic fatigue syndrome. J Womens Health (Larchmt) 2010;19:239-244.
  92. Vermeulen RCW, Kurk RM, Visser FC, Sluiter W, Scholte HR: Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. J Transl Med 2010;8:93.
  93. Booth NE, Myhill S, McLaren-Howard J: Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Int J Clin Exp Med 2012;5:208-220.
  94. Cleare AJ: The HPA axis and the genesis of chronic fatigue syndrome. Trends Endocrinol Metab 2004;15:55-59.
  95. Baumeister D, Lightman S, Pariante C: The interface of stress and the HPA axis in behavioural phenotypes of mental illness. Curr Top Behav Neurosci 2014;18:13-24.
  96. Tsigos C, Chrousos GP: Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002;53:865-871.
  97. Powell DJH, Liossi C, Moss-Morris R, Schlotz W: Unstimulated cortisol secretory activity in everyday life and its relationship with fatigue and chronic fatigue syndrome: a systematic review and subset meta-analysis. Psychoneuroendocrinology 2013;38:2405-2422.
  98. Silverman MN, Sternberg EM: Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci 2012;1261:55-63.
  99. Khani S, Tayek JA: Cortisol increases gluconeogenesis in humans: its role in the metabolic syndrome. Clin Sci (Lond) 2001;101:739-747.
  100. Cleare AJ, Heap E, Malhi GS, Wessely S, O'Keane V, Miell J: Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet 1999:353:455-458.
  101. Poteliakhoff A: Adrenocortical activity and some clinical findings in acute and chronic fatigue. J Psychosom Res 1981;25:91-95.
  102. Demitrack MA, Dale JK, Straus SE, et al: Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991;73:1224-1234.
  103. Papadopoulos AS, Cleare AJ: Hypothalamic-pituitary-adrenal axis dysfunction in chronic fatigue syndrome. Nat Rev Endocrinol 2012;8:22-32.
  104. Tak LM, Cleare AJ, Ormel J, et al: Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders. Biol Psychol 2011;87:183-194.
  105. Wilhelm I, Born J, Kudielka BM, Schlotz W, Wűst S: Is the cortisol awakening rise a response to awakening? Psychoneuroendocrinology 2007;32:358-366.
  106. Roberts AD, Wessely S, Chalder T, Papadopoulos A, Cleare AJ: Salivary cortisol response to awakening in chronic fatigue syndrome. Br J Psychiatry 2004;184:136-141.
  107. Nater UM, Maloney E, Boneva RS, et al: Attenuated morning salivary cortisol concentrations in a population-based study of persons with chronic fatigue syndrome and well controls. J Clin Endocrinol Metab 2008;93:703-709.
  108. Nijhof SL, Rutten JMTM, Uiterwaal CSPM, Bleijenberg G, Kimpen JLL, Putte EM: The role of hypocortisolism in chronic fatigue syndrome. Psychoneuroendocrinology 2014;42:199-206.
  109. Heim C, Nater UM, Maloney E, Boneva R, Jones JF, Reeves WC: Childhood trauma and risk for chronic fatigue syndrome: association with neuroendocrine dysfunction. Arch Gen Psychiatry 2009;66:72-80.
  110. Borsini a, Hepgul N, Mondelli V, Chalder T, Pariante CM: Childhood stressors in the development of fatigue syndromes: a review of the past 20 years of research. Psychol Med 2013;1-15.
  111. Strickland P, Morriss R, Wearden A, Deakin B: A comparison of salivary cortisol in chronic fatigue syndrome, community depression and healthy controls. J Affect Disord 1998;47:191-194.
  112. Jerjes WK, Cleare a J, Wessely S, Wood PJ, Taylor NF: Diurnal patterns of salivary cortisol and cortisone output in chronic fatigue syndrome. J Affect Disord 2005;87:299-304.
  113. Papadopoulos A, Ebrecht M, Roberts ADL, Poon L, Rohleder N, Cleare AJ: Glucocorticoid receptor mediated negative feedback in chronic fatigue syndrome using the low dose (0.5 mg) dexamethasone suppression test. J Affect Disord 2009;112:289-294.
  114. Young AH, Sharpe M, Clements A, Dowling B, Hawton KE, Cowen PJ: Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome (neurasthenia). Biol Psychiatry 1998;43:236-237.
  115. Wood B, Wessely S, Papadopoulos A, Poon L, Checkley S: Salivary cortisol profiles in chronic fatigue syndrome. Neuropsychobiology 1998;37:1-4.
  116. Gaab J, Hüster D, Peisen R, et al: Low-dose dexamethasone suppression test in chronic fatigue syndrome and health. Psychosom Med 2002;64:311-318.
  117. Gaab J, Engert V, Heitz V, Schad T, Schürmeyer TH, Ehlert U: Associations between neuroendocrine responses to the Insulin Tolerance Test and patient characteristics in chronic fatigue syndrome. J Psychosom Res 2004;56:419-424.
  118. Gaab J, Rohleder N, Heitz V, et al: Stress-induced changes in LPS-induced pro-inflammatory cytokine production in chronic fatigue syndrome. Psychoneuroendocrinology 2005;30:188-198.
  119. İzgi H, Gökçe C, Çals M, et al: Investigation of the hypothalamopituitary - adrenal axis by low-dose (1 g) adrenocorticotrophic hormone test and metyrapone test in patients with chronic fatigue syndrome. Endocrinologist 2005;15:89-92.
  120. Van Den Eede F, Moorkens G, Van Houdenhove B, Cosyns P, Claes SJ: Hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome. Neuropsychobiology 2007;55:112-120.
  121. Inder WJ, Prickett TCR, Mulder RT: Normal opioid tone and hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome despite marked functional impairment. Clin Endocrinol (Oxf) 2005;62:343-348.
  122. Jerjes WK, Taylor NF, Wood PJ, Cleare AJ: Enhanced feedback sensitivity to prednisolone in chronic fatigue syndrome. Psychoneuroendocrinology 2007;32:192-198.
  123. Visser J, Blauw B, Hinloopen B, et al: CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone. J Infect Dis 1998;177:451-454.
  124. Visser J, Lentjes E, Haspels I, et al: Increased sensitivity to glucocorticoids in peripheral blood mononuclear cells of chronic fatigue syndrome patients, without evidence for altered density or affinity of glucocorticoid receptors. J Investig Med 2001;49:195-204.
  125. Van Den Eede F, Moorkens G, Hulstijn W, et al: Combined dexamethasone/corticotropin-releasing factor test in chronic fatigue syndrome. Psychol Med 2008;38:963-973.
  126. Catley D, Kaell a T, Kirschbaum C, Stone AA: A naturalistic evaluation of cortisol secretion in persons with fibromyalgia and rheumatoid arthritis. Arthritis Care Res 2000;13:51-61.
  127. Klingmann PO, Kugler I, Steffke TS, Bellingrath S, Kudielka BM, Hellhammer DH: Sex-specific prenatal programming: a risk for fibromyalgia? Ann N Y Acad Sci 2008;1148:446-55.
  128. Riva R, Mork PJ, Westgaard RH, Rø M, Lundberg U: Fibromyalgia syndrome is associated with hypocortisolism. Int J Behav Med 2010;17:223-233.
  129. Macedo J a, Hesse J, Turner JD, Meyer J, Hellhammer DH, Muller CP: Glucocorticoid sensitivity in fibromyalgia patients: decreased expression of corticosteroid receptors and glucocorticoid-induced leucine zipper. Psychoneuroendocrinology 2008;33:799-809.
  130. McLean S a, Williams D a, Harris RE, et al: Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum 2005;52:3660-3669.
  131. Griep EN, Boersma JW, de Kloet ER: Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993;20:469-474.
  132. Griep EN, Boersma JW, Lentjes EG, Prins AP, van der Korst JK, de Kloet ER: Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol 1998;25:1374-1381.
  133. Riedel W, Layka H, Neeck G: Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Z Rheumatol 1998;57(suppl 2):81-87.
  134. Calis M, Gökçe C, Ates F, et al: Investigation of the hypothalamo-pituitary-adrenal axis (HPA) by 1 microg ACTH test and metyrapone test in patients with primary fibromyalgia syndrome. J Endocrinol Invest 2004;27:42-46.
  135. Kirnap M, Colak R, Eser C, Ozsoy O, Tutus A, Kelestimur F: A comparison between low-dose (1 microg), standard-dose (250 microg) ACTH stimulation tests and insulin tolerance test in the evaluation of hypothalamo-pituitary-adrenal axis in primary fibromyalgia syndrome. Clin Endocrinol (Oxf) 2001;55:455-459.
  136. Van Denderen JC, Boersma JW, Zeinstra P, Hollander AP, van Neerbos BR: Physiological effects of exhaustive physical exercise in primary fibromyalgia syndrome (PFS): is PFS a disorder of neuroendocrine reactivity? Scand J Rheumatol 1992;21:35-37.
  137. Gursel Y, Ergin S, Ulus Y, Erdogan MF, Yalcin P, Evcik D: Hormonal responses to exercise stress test in patients with fibromyalgia syndrome. Clin Rheumatol 2001;20:401-405.
  138. Wingenfeld K, Wagner D, Schmidt I, Meinlschmidt G, Hellhammer DH, Heim C: The low-dose dexamethasone suppression test in fibromyalgia. J Psychosom Res 2007;62:85-91.
  139. Lyall M, Peakman M, Wessely S: A systematic review and critical evaluation of the immunology of chronic fatigue syndrome. J Psychosom Res 2003;55:79-90.
  140. Pariante C: Chronic fatigue syndrome and the immune system: ‘findings in search of meanings'. Brain Behav Immun 2009;23:325-326.
  141. Cleare AJ, O'Keane V, Miell JP: Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome. Psychoneuroendocrinology 2004;29:724-732.

Article / Publication Details

First-Page Preview
Abstract of  

Published online: March 30, 2015
Cover Date: 2015

Number of Print Pages: 17
Number of Figures: 2
Number of Tables: 3

ISBN: 978-3-318-02966-6 (Print)
eISBN: 978-3-318-02967-3 (Online)


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Stay Up to Date Banner Stay Up to Date Banner
TOP